While Gearing Up To Supply Biosimilars To U.S. And EU Markets, Will Leading Chinese Biotech 3SBio Be M&A Target?

BEIJING - One of China's leading biopharmaceutical developers, 3SBio, reported solid earnings for the third quarter of 2010, which could help make the firm ripe for a takeover by an international player